ES2214013T3 - Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso. - Google Patents

Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.

Info

Publication number
ES2214013T3
ES2214013T3 ES99907846T ES99907846T ES2214013T3 ES 2214013 T3 ES2214013 T3 ES 2214013T3 ES 99907846 T ES99907846 T ES 99907846T ES 99907846 T ES99907846 T ES 99907846T ES 2214013 T3 ES2214013 T3 ES 2214013T3
Authority
ES
Spain
Prior art keywords
antagonist
preparation
aii
production
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99907846T
Other languages
English (en)
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2214013T3 publication Critical patent/ES2214013T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparación de liberación prolongada, que comprende un compuesto no peptídico que tiene actividad antagonista de angiotensina II, y que tiene un enlace de éter o un grupo carbonílico, su profármaco o su sal, y un polímero biodegradable.
ES99907846T 1998-03-04 1999-03-03 Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso. Expired - Lifetime ES2214013T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04

Publications (1)

Publication Number Publication Date
ES2214013T3 true ES2214013T3 (es) 2004-09-01

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99907846T Expired - Lifetime ES2214013T3 (es) 1998-03-04 1999-03-03 Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.

Country Status (21)

Country Link
US (2) US6589547B1 (es)
EP (1) EP1058541B1 (es)
KR (1) KR20010086245A (es)
CN (1) CN1291888A (es)
AT (1) ATE258430T1 (es)
AU (1) AU2745199A (es)
BR (1) BR9908474A (es)
CA (1) CA2318446C (es)
DE (1) DE69914460T2 (es)
EE (1) EE200000499A (es)
ES (1) ES2214013T3 (es)
HU (1) HUP0101439A3 (es)
ID (1) ID25640A (es)
IL (1) IL137979A0 (es)
LT (1) LT4800B (es)
LV (1) LV12585B (es)
NO (1) NO20004350L (es)
PL (1) PL342684A1 (es)
SK (1) SK11902000A3 (es)
WO (1) WO1999044590A1 (es)
ZA (1) ZA991706B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
BR0010084A (pt) 1999-04-28 2002-01-15 Takeda Chemical Industries Ltd Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL356422A1 (en) * 2000-02-18 2004-06-28 Takeda Chemical Industries, Ltd. Tnf-alpha inhibitors
WO2001060410A1 (fr) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Preparations a liberation lente contenant un compose physiologiquement actif peu soluble dans l'eau et methode de production et d'utilisation desdites preparations
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
CA2426674A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
CA2466659A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20070270477A1 (en) * 2004-10-07 2007-11-22 Takeda Pharmaceutical Company Limited Agent for Prophylaxis or Treatment of Metabolic Syndrome
WO2006046528A1 (ja) * 2004-10-29 2006-05-04 Kowa Co., Ltd. 糸球体疾患治療剤
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
SI1863801T1 (sl) * 2005-03-30 2010-12-31 Takeda Pharmaceutical Benzimidazolni derivat in njegova uporaba
EP1926705B3 (en) * 2005-08-22 2010-09-15 Alembic Limited Process for preparing valsartan
MX2009001429A (es) * 2006-08-10 2009-02-17 Takeda Pharmaceutical Composicion farmaceutica.
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
BRPI0720582B1 (pt) 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
AR076913A1 (es) 2009-05-20 2011-07-20 Boehringer Ingelheim Vetmed Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucion
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
EP0403158A3 (en) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
DK0479903T3 (da) 1989-06-30 1996-03-18 Du Pont Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
EP0411507B1 (en) 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (es) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
JPH06510763A (ja) * 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ATE537858T1 (de) * 1993-07-19 2012-01-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
WO1997001331A2 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
CN1214682A (zh) 1996-03-29 1999-04-21 史密丝克莱恩比彻姆公司 Eprosartan二水合物及其制备和制剂方法
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica

Also Published As

Publication number Publication date
ID25640A (id) 2000-10-19
ATE258430T1 (de) 2004-02-15
CN1291888A (zh) 2001-04-18
NO20004350D0 (no) 2000-09-01
HUP0101439A3 (en) 2002-09-30
IL137979A0 (en) 2001-10-31
SK11902000A3 (sk) 2001-02-12
LT4800B (lt) 2001-06-25
LV12585B (en) 2001-03-20
US6589547B1 (en) 2003-07-08
DE69914460D1 (de) 2004-03-04
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13
NO20004350L (no) 2000-10-03
DE69914460T2 (de) 2004-10-28
US7294344B2 (en) 2007-11-13
KR20010086245A (ko) 2001-09-10
CA2318446C (en) 2008-09-23
PL342684A1 (en) 2001-07-02
US20030198676A1 (en) 2003-10-23
ZA991706B (en) 2000-10-03
HUP0101439A2 (hu) 2001-10-28
WO1999044590A1 (en) 1999-09-10
EP1058541B1 (en) 2004-01-28
LT2000082A (en) 2001-03-26
LV12585A (en) 2000-12-20
BR9908474A (pt) 2000-12-05
AU2745199A (en) 1999-09-20
CA2318446A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
ES2214013T3 (es) Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
ATE258043T1 (de) Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe
DE60108925D1 (de) Rollback Dichtung für Scheibenbremse
NO20016315L (no) Kutteapparat for rörledninger
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
NO20031843L (no) Metylfenidatmodifiserte frigjöringspreparater
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
BR0100652B1 (pt) sistema hidráulico.
DE50114543D1 (de) Laserverstärkersystem
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
DE50111889D1 (de) Sicherheitssysteme für Zerkleinerungsmaschinen
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
NO20015892D0 (no) Inhibitorer av metallproteinaser
DE60038007D1 (de) Teilchenstrahlgerät
BR0110206A (pt) Inibidores de peptìdeo deformilase
BR0016991B1 (pt) mÉtodo para a sÍntese de hidrazodicarbonamida.
BR0106134B1 (pt) sistema hidráulico.
FR2817648B1 (fr) Reflecteur sonore actif
IT1317262B1 (it) Componente di un impianto freno
NO20016152L (no) Aktivitetsrapportgenerering
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
ES1044080Y (es) Señalizador perfeccionado para automoviles de uso publico.
ECSP003741A (es) Una combinacion farmaceutica que tiene una gran permeabilidad a traves de la membrana celular
ES1044839Y (es) Tapas-puerta de desarrollo curvo para mobiliario.
FI20000531A0 (fi) Järjestelmä diafragman kiinnittämiseksi